About the Event
Kineta, Inc. (Nasdaq: KA) is a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance. With the company’s multiple programs in development and strong strategic partnerships, they are eligible for billions in milestone payments and royalties, though their market cap is currently just $25M.
Kineta recently announced an update on its ongoing Phase 1/2 clinical trial evaluating KVA12123 in patients with advanced solid tumors.
Watch this webinar with Kineta CEO, Shawn Iadonato for a complete review of their trial to date and look at the road ahead.